Evidence map›Paper›PMID 42876482›Full record

ArticleFrontiers in physiology2026

Ceramidase is involved in metabolic reprogramming of fibroblasts under hypoxia conditions.

Michela Terlizzi, Emmanuel D'Andria, Chiara Colarusso, Simone Di Caprio, Anna Falanga, Maria Rosaria Lauro, Rosario Salvi, Rosalinda Sorrentino

Abstract read
In one paragraph

Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michela TerlizziLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.
Emmanuel D'AndriaLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.
Chiara ColarussoBiogem Scarl, Istituto di Ricerche Genetiche "Gaetano Salvatore" & CaReBios surl, Ariano Irpino, Avellino, Italy.
Simone Di CaprioLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.
Anna FalangaLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.
Maria Rosaria LauroLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.
Rosario SalviComplex Operating Unit of Thoracic Surgery, Azienda Ospedaliera di Rilievo Nazionale "San Giuseppe Moscati" (A.O.R.N. Giuseppe Moscati), Avellino, Italy.
Rosalinda SorrentinoLaboratory of Applied Physiology and Pharmacology, Department of Pharmacy, DIFARMA, University of Salerno, Fisciano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Physiological metabolic reprogramming is a cells strategy to resist/counteract stress to preserve homeostasis. Hypoxia is an important stress stimulus that can promote tissue remodeling and fibrosis, in which alterations in sphingolipid metabolism may contribute to fibroblast responses. Here, we investigated the potential role of acid ceramidase (ASAH1), a key enzyme of the sphingolipid salvage pathway, in fibroblast adaptation to hypoxic stress. Methods: Human fibroblasts were exposed to hypoxia for 24, 48, and 72 hours, and metabolic and redox changes were investigated following pharmacological inhibition of acid ceramidase with D-Nmappd. These findings were complemented by analyses of publicly available bulk and single-cell RNA sequencing datasets from idiopathic pulmonary fibrosis (IPF) lungs. Results: Hypoxic fibroblasts showed metabolic remodeling involving glucose-, amino acid-, and redox-associated pathways, together with changes consistent with an adaptive antioxidant response, including alterations in the GSH/GSSG balance. Pharmacological inhibition of acid ceramidase under hypoxia was associated with changes in carnitine metabolism and long-chain fatty acid β-oxidation, reduced GSH and GSSG levels, and decreased expression of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2), Superoxide dismutase 2 (SOD2), and 8-Oxoguanine DNA Glycosylase 1 (OGG1). In IPF lung tissue, ASAH1 expression was associated with glycolytic and redox-related genes. Single-cell analysis showed that ASAH1-expressing IPF fibroblasts were enriched in transcriptional programs related to hypoxic responses and oxidative stress regulation and displayed features associated with a less activated phenotype. Discussion: Overall, these findings suggest that acid ceramidase/ASAH1 is associated with fibroblast metabolic and redox adaptation to hypoxic stress and may influence fibroblast activation in IPF.

Indexed as

ceramidasefibroblastshypoxiametabolic reprogrammingpulmonary fibrosis

Identifiers

PMID42876482
PMCPMC13661358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.